AYTU BIOPHARMA, INC Impairment of Intangible Assets (Excluding Goodwill)
AYTU BIOPHARMA, INC (AYTU) reported Impairment of Intangible Assets (Excluding Goodwill) of $0 for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-22.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill · last filed 2026-09-22
- AYTU BIOPHARMA, INC impairment of intangible assets (excluding goodwill) for fiscal 2026 was $0.00, a 100.00% decline from fiscal 2025.
- AYTU BIOPHARMA, INC impairment of intangible assets (excluding goodwill) for fiscal 2025 was $8.30M.
- AYTU BIOPHARMA, INC impairment of intangible assets (excluding goodwill) for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- AYTU BIOPHARMA, INC impairment of intangible assets (excluding goodwill) for fiscal 2023 was $5.60M, a 21.13% decline from fiscal 2022.
| Period end | Impairment of Intangible Assets (Excluding Goodwill) 12 month |
|---|---|
| 2026-06-30 | $0.00 10-K · filed 2026-09-22 |
| 2025-06-30 | $8.30M 10-K · filed 2026-09-22 |
| 2024-06-30 | $0.00 10-K · filed 2025-09-23 |
| 2023-06-30 | $5.60M 10-K · filed 2024-09-26 |
| 2022-06-30 | $7.10M 10-K · filed 2023-10-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |